Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Acridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.94 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.94 |
| ▸ | MAPT | P10636 | 3/20 | 0.94 |
| ▸ | HPGD | P15428 | 3/20 | 0.94 |
| ▸ | GLA | P06280 | 2/20 | 0.94 |
| ▸ | NQO2 | P16083 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acridine SCHEMBL2401648 | 1.00 | ALDH1A1 (0.94) | ALDH1A1MAPTHPGDGLAACHE | |
| Acridine SCHEMBL3045498 | 0.97 | ALDH1A1 (1.00) | ALDH1A1MAPTHPGDGLAACHE | |
| Acridine SCHEMBL4972293 | 0.97 | ALDH1A1 (1.00) | ALDH1A1MAPTHPGDGLAACHE | |
| Acridine SCHEMBL8339 | 0.97 | ALDH1A1 (1.00) | ALDH1A1MAPTHPGDGLAACHE | |
| Acridine SCHEMBL29352289 | 0.97 | ALDH1A1 (1.00) | ALDH1A1MAPTHPGDGLAACHE | |
| Acridine SCHEMBL1772714 | 0.97 | ALDH1A1 (1.00) | ALDH1A1MAPTHPGDGLAACHE | |
| Anthracene SCHEMBL9879830 | 0.94 | MAPT (0.94) | ALDH1A1MAPTHPGDGLAACHE | |
| Acridine SCHEMBL1551975 | 0.94 | ALDH1A1 (0.94) | ALDH1A1MAPTHPGDGLAACHE | |
| Acridine SCHEMBL2394207 | 0.94 | ALDH1A1 (0.94) | ALDH1A1MAPTHPGDGLAACHE | |
| Acridine SCHEMBL641951 | 0.94 | ALDH1A1 (0.94) | ALDH1A1MAPTHPGDGLAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190125734-A1 | COMPOSITION FOR TREATING OR PREVENTING ATOPIC DERMATITIS | NANOEGG RESEARCH LABORATORIES, INC. (JP) | 2019-05-02 | — | — | US | claimed |
| EP-3456353-A1 | COMPOSITION FOR TREATING OR PREVENTING ATOPIC DERMATITIS | Nanoegg Research Laboratories, Inc. (JP) | 2019-03-20 | — | — | EP | claimed |
| WO-2020158894-A1 | COMPOSITION CONTAINING POLYSULFIDE COMPOUND | 協和発酵バイオ株式会社 | 2020-08-06 | — | — | WO | disclosed |
| US-20190125734-A1 | COMPOSITION FOR TREATING OR PREVENTING ATOPIC DERMATITIS | NANOEGG RESEARCH LABORATORIES, INC. (JP) | 2019-05-02 | — | — | US | disclosed |
| EP-3456353-A1 | COMPOSITION FOR TREATING OR PREVENTING ATOPIC DERMATITIS | Nanoegg Research Laboratories, Inc. (JP) | 2019-03-20 | — | — | EP | disclosed |
| CN-102325530-A | 5- (2- { [6- (2, 2-difluoro-2-phenylethoxy) hexyl ] amino } -1-hydroxyethyl) -8-hydroxyquinolin-2 (1H) -one for the treatment of lung function | ALMIRALL SA | 2012-01-18 | — | — | CN | disclosed |
| CN-102317264-A | 5- (2- { [6- (2, 2-difluoro-2-phenylethoxy) hexyl ] amino } -1-hydroxyethyl) -8-hydroxyquinolin-2 (1H) -one and its use in the treatment of lung diseases | ALMIRALL SA | 2012-01-11 | — | — | CN | disclosed |
| US-4647518-A | Light-emitting display component and method for light-emitting display using the same | CANON KABUSHIKI KAISHA (JP) | 1987-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190125734-A1 | COMPOSITION FOR TREATING OR PREVENTING ATOPIC DERMATITIS | CHRM3, ACHE, CHRNB1 | ACHE 2/4885HTR3A 772/4885ALDH1A1 1959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.